Tag Archives: Invitae

Benchmark Co. Releases a Buy Rating on Invitae

In a report released today, Raymond Myers from Benchmark Co. reiterated a Buy rating on Invitae (NYSE: NVTA), with a price target of $16. The company’s shares closed last Friday at $11.06. According to TipRanks.com, Myers is a 3-star analyst

An Insider at Invitae (NYSE: NVTA) is Selling Shares

Yesterday, an Insider at Invitae (NYSE: NVTA), Patty Dumond, sold shares of NVTA for $12.06K. In addition to Patty Dumond, 15 other NVTA executives reported Sell trades in the last month. Following Patty Dumond’s last NVTA Sell transaction on February

The Chief Financial Officer of Invitae (NYSE: NVTA) is Selling Shares

Yesterday, the Chief Financial Officer of Invitae (NYSE: NVTA), Lee Bendekgey, sold shares of NVTA for $20.12K. In addition to Lee Bendekgey, 15 other NVTA executives reported Sell trades in the last month. Following Lee Bendekgey’s last NVTA Sell transaction

A Director at Invitae (NYSE: NVTA) is Buying Shares

Today, a Director at Invitae (NYSE: NVTA), Eric Aguiar, bought shares of NVTA for $62.8K. Following this transaction Eric Aguiar’s holding in the company was increased by 100% to a total of $25.46 million. In addition to Eric Aguiar, 2

Analysts Offer Insights on Healthcare Companies: Invitae (NYSE: NVTA) and Haemonetics Corp. (NYSE: HAE)

Analysts fell to the sidelines weighing in on Invitae (NYSE: NVTA) and Haemonetics Corp. (NYSE: HAE) with neutral ratings,indicating that the experts are neither bullish nor bearish on the stocks. Invitae (NYSE: NVTA) In a report released today, Raymond Myers